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BRIEF DEFINITIVE REPORT by SDS-PAGE and further purified by reversed-phase HPLC on an analytical CN-propyl column (4.6 x 250 mm, 5 Am, wide-pore ; Baker Research Products, Phillipsburg, NJ) eluted (0.5 ml/min) with a gradient of0-20% acetonitrile in 0.1% trifluoroacetic acid with an increment of 0.33% per minute. NAP-2 was purified as described (1) . The purity was confirmed by NH2-terminal sequencing of the first 12 residues .
BiologicalAssays. Neutrophil chemotaxis (9) , cytosolic free calcium changes (7) , and elastase release (7) were determined according to established methods .
Results
Peptide Purification.
PBP and CTAP-III were resolved from each other, and completely separated from PF4 by heparin-Sepharose chromatography (data not shown). Upon reversed-phase HPLC, NAP-2, PBP, CTAP-III, and PF4 eluted with different retention times (Fig. 2) . Electrophoretically pure NAP-2, eluting as a single peak from a C4-column (1), was recovered as a doublet from the CN-propyl column (Fig.  2) , which was used to separate NAP-2 from the other species . HPLC-purified peptides migrated as single bands in SDS-PAGE (not shown). They were identified by NH2-terminal sequencing of the first 12 residues . A single sequence was obtained for each species, indicating that they were indeed analytically pure.
The release supernatants of fresh thrombin-stimulated platelets contained PBP, CTAP-III, and PF4, but no 0-thromboglobulin (OTG) or NAP-2 .
Elastase Release.
Elastase release from cytochalasin B-pretreated neutrophils was the biological assay used for NAF/NAP-1 (7) and NAP-2 (1) . Both were now compared with the peptides from the a-granules . As shown in Fig. 3 a, NAP-2 induced significant release of elastase at concentrations between 0.3 and 100 nM, while only minimal activity (N2% of that of NAP-2) was obtained with PBP at 100 nM, the highest concentration used. CTAP-III, PF-4, and the lower concentrations of PBP were inactive. NAP-2 was effective in the same molarity range as NAF/NAP-1, but was about half as potent .
Cytosolic Free Calcium Changes .
Stimulus-dependent fura-2 fluorescence changes were recorded, and the rate offluorescence increase was determined. A similar, progressive increase in the rate of the calcium rise was observed after stimulation with 0.1 to 100 nM NAP-2 and NAF/NAP-1 (Fig. 3 b) . PBP, CTAP-III, and PF4 were virtually inactive up to a concentration of 10 nM, but showed some effect at 100 nM. PBP was slightly more active than CTAP-III and PF4 . Reversed-phase HPLC of purified NAP-2, PBP, CTAP-III, andPF4 on an analytical CN-propyl column . The retention times were 23 .9 min for NAP-2, 36 .0 min for PBP, 39 .6 min for CTAP-III, and 47 .1 min for PF4. effect at 1 nM, and showed low levels of activity at 10 and 100 nM . PBP was again slightly more active than CTAP-III . Fig. 4 b shows that NAP-2 and NAF/NAP-1 were equipotent with C5a, the most active naturally occurring chemotactic peptide described so far.
Discussion
This study shows that NAP-2 is a powerful activator of human neutrophils, inducing cytosolic free calcium changes, chemotaxis, and exocytosis at concentrations between 0.3 and 10 nM, while its homologues, the platelet a-granule proteins PBP, CTAP-III, and PF 4, are practically inactive at concentrations up to 100 nM . NAP-2 is equipotent with NAF/NAP-1 and C5a as a stimulus for chemotaxis, but weaker than these and other agonists as an inducer of exocytosis .
Of the platelet ct-granule proteins studied, PF4 was the first to be characterized (5). It was reported to be chemotactic for neutrophils, monocytes (10, 11) , and fibroblasts (12) , and to induce neutrophil adherence and granule release (11) . Except in the case of fibroblasts (12) , these responses were obtained at PF4 concentrations between 100 nM and -20 gM (11, 12) , i.e., 100-10,000-fold higher than NAP-2, NAF/NAP-1, and C5a in the present study. CTAP-III was reported to enhance mucopolysaccharide synthesis and other metabolic processes in synovial cells (4, 13) and to be mitogenic for fibroblasts (4), but not for 3T3 cells (3) . Such effects were not obtained with the CTAP-III precursor PBP (3) and the CTAP-III cleavage product DWG (4). None of these peptides were reported to activate neutrophils.
Our observation that PF4 is not chemotactic for neutrophils does not necessarily contradict the earlier findings obtained at higher concentrations (10, 11) . However, in view of the high potency of NAP-2, it must be realized that a minimal contamina-tion with this peptide could account for the neutrophil-stimulating effects previously attributed to PF 4.
Platelets have long been thought to participate in intravascular inflammatory processes through the release of vasoactive, proexudative, and phagocyte-activating products (14) . Neutrophils, which are often found in association with platelet aggregates (15, 16) , are presumably attracted by chemotactic mediators released as a consequence of platelet activation . Up to now, platelet-activating factor was considered the most potent of these attractants (17) . The recent identification of NAP-2 as a powerful chemotactic fragment of PBP, however, suggests the existence of an alternative mechanism of neutrophil recruitment that is related to ct-granule exocytosis. The recruitment of neutrophils into platelet aggregates and thrombi via plateletderived chemotaxins may constitute a mechanism for the degradation of thrombotic deposits and the recanalization of obstructed vessels. On the other hand, activated neutrophils could aggravate the course of thrombotic diseases and their sequelae, as in atherosclerosis, by inducing inflammation and tissue damage .
Summary
Platelet basic protein (PBP), connective tissue-activating peptide III (CTAP-III), and platelet factor 4 (PF4) were purified from human platelet release supernatants by heparin-Sepharose ion-exchange and reversed-phase HPLC, and their neutrophilactivating effects were compared with those of NAP-2, a peptide of 70 amino acids corresponding to part of the sequence of PBP (1) and with sequence homology to NARNAP-1 . NAP-2-induced elastase release and a rise in cytosolic free Ca 2+ at concentrations between 0.3 and 100 nM, and neutrophil chemotaxis at concentrations between 0.03 and 10 nM . It was half as potent as NAF/NAP-1 in inducing exocytosis but showed the same activity in the other responses. By contrast, only minimal if any effects were obtained with PBP, CTAP-III, and PF4 up to 100 nM .
NAP-2 thus appears to behave like a typical chemotactic receptor agonist. It could be generated from PBP and/or CTAP-III released from activated platelets and lead to the accumulation of neutrophils in platelet aggregates.
